Clinical Trial

Adjuvant Immunotherapy After Salvage Surgery in Head and Neck Squamous Cell Carcinoma

Study acronym: ADJORL1
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
Two randomized trials of reirradiation after salvage surgery have been conducted by the GETTEC and GORTEC collaborative groups, both members of the French HN Intergroup: The first trial compared reirradiation and a "wait and see attitude" and was published in 2008 \[1\]. The second trial compared two modalities of reirradiation. Our hypothesis is that adjuvant treatment with immunotherapy will lead to a DFS similar to that observed in previous trials of post-operative reirradiation with possibly lower toxicity.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2018-01-15; most recent amendment 2025-05-07.
Status change: Not Yet Recruiting → Recruiting 2022-04-04
Trial Details
NCT Number NCT03406247
Lead Sponsor Gustave Roussy, Cancer Campus, Grand Paris
Conditions Head and Neck Squamous Cell Carcinoma
Enrollment 140 participants
Start Date 2018-02-12
Primary Completion 2027-11 (estimated)
Study Completion 2027-11 (estimated)
Updated on ClinicalTrials.gov 2025-05-08